AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

AbbVie (NYSE:ABBV – Get Free Report) had its price target upped by stock analysts at Guggenheim from $212.00 to $214.00 in a ...

UnitedHealth Group, AbbVie, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer to equities in companies that are ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.

THE TV – “Feel tired? Out of energy? Then you need Oxyoxt.” “I used to have broken bones, cancer of the thumbs and nightmares ...

Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $205 and keeps a Buy rating on the shares. AbbVie repeated its usual beat in ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, expectations were $2.98. Operator: Good morning and thank you for standing by.